Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
